DILIsym is being used to impact drug development programs in a big way!
DILIsym has been utilized by our clients for help with their liver safety goals within a number of high profile drug development programs. Important DILIsym application examples include:
- Comparison of ubrogepant with prior in-class molecules for DILI potential, which was included in an FDA review of the ubrogepant safety data
- Comparison of lixivaptan’s liver safety profile with tolvaptan, which was submitted to the FDA as part of the new IND application for lixivaptan
- Mechanistic analysis of acetaminophen’s carcinogenic potential, which was submitted to the California Office of Environmental Health Hazard Assessment regarding Proposition 65 as part of the weight of evidence suggesting no cancer risk; FDA agreed
- Mechanistic analyses of the liver safety of remdesivir, tolvaptan, pexidartinib, and TAK-875
- Comparison of the liver safety mechanisms of several macrolide antibiotics as part of the solithromycin new drug application advisory committee meeting
- Liver safety biomarker analyses for entolimod and GGF2
- Dose optimization for a novel antibiotic, BAL30072
Regulatory Interactions
Given the high social and economic costs associated with late stage drug failures, the U.S. FDA has been assessing the added value of computer modeling in regulatory decision making as a way of predicting drug safety and efficacy during drug development. A major effort in the Center for Drug Evaluation and Research is the development and use of computer simulations to predict drug toxicity and to understand the mechanisms responsible for unexpected adverse events. Liver and kidney toxicity remain areas in which safety concerns continue to lead to drug failures across all phases of drug development. The FDA was involved in a Cooperative Research and Development Agreement (CRADA) that led to the formation of the DILI-sim Initiative and the ultimate development of the DILIsym software platform. Recently, the FDA renewed their DILIsym licenses package. A commentary published by employees of the FDA on the DILIsym software praised early examples of DILIsym use and commented on the prospect of future predictions. Another review paper including an FDA author provided an overview of DILIsym. Finally, a published book edited by an FDA employee included a complete chapter on DILIsym. Many application examples of DILIsym have also been submitted to the FDA, as noted above. Submissions to the EMA and PMDA have also occurred for some of the same development programs and others.
What do NURTEC™ ODT, TURALIO®, lixivaptan, solithromycin, JYNARQUE®, VEKLURI®, and UBRELVY® have in common?
To learn more on the DILIsym® Applications in Drug Development, register for our 2021 DILIsym® Panel-driven Webinar on April 29. Join us for Q&A session with Dr. Vlad Coric (CEO of Biohaven Pharmaceuticals), Dr. Lorenzo Pellegrini (COO of Palladio Biosciences), Dr. Paul B. Watkins, a hepatologist and DILI experts. Register Now